Ivan Oransky
IN AN UNUSUAL move last month, the journal Clinical Infectious Diseases published a critique by 109 clinical researchers of an investigative report by David Willman of the Los Angeles Times. Willman had probed whether Thomas Walsh, a senior researcher at the National Institutes of Health, had manipulated a trial to give a new drug a better chance of succeeding. Willman's ... (Full article: 775 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
